Anti-Mouse CD178 (FasL) – Purified in vivo GOLD™ Functional Grade

Clone MFL3 is primarily used in vivo in mice to block FasL-mediated apoptosis, thereby modulating immune responses and facilitating the study of FasL-related functions in areas such as immunology, tumor biology, and inflammation.

Key in vivo applications include:

• Blocking FasL-induced apoptosis: By inhibiting Fas ligand (FasL, CD178) interaction with its receptor (Fas/CD95), MFL3 enables researchers to study the role of FasL in immune cell death, such as in peripheral tolerance, autoimmunity, and immune privilege.
• Modulating immune responses: MFL3 is used to evaluate how FasL influences T cell and NK cell function, and to dissect mechanisms of immune evasion by tumors that overexpress FasL, contributing to local immune suppression.
• Investigating tumor immune evasion: Tumors sometimes overexpress FasL to induce apoptosis in infiltrating lymphocytes; in vivo administration of MFL3 can disrupt this mechanism and help researchers study tumor-immune system interactions.
• Studying inflammation and tissue injury: FasL is implicated in various inflammatory and tissue injury models, especially where immune-mediated apoptosis contributes to disease. Blocking FasL with MFL3 helps identify its involvement in such settings.
• Research on organ-specific immune regulation: Since FasL is expressed on tissues with immune privilege (e.g., eye, testis), MFL3 can be used to study immune tolerance and privilege mechanisms.

Additional notes:

• MFL3 antibodies for in vivo use are specifically formulated to be ultra-low in endotoxins, highly pure, and tested for murine pathogens to ensure they do not confound experimental results.
• Typical experimental models include those related to apoptosis, immunology, tumor suppressors, and cell death pathways.
• While MFL3 is also used in vitro (e.g., flow cytometry, immunohistochemistry), its functional blocking of FasL in vivo is the characteristic application cited across vendors and technical resources.

In summary, MFL3’s main in vivo utility in mice is as a highly specific blocking antibody for FasL, supporting research in apoptosis, immune regulation, cancer biology, and inflammatory disease models.

The most commonly used antibodies or proteins with MFL3 (anti-mouse FasL) in the literature are anti-CD3 and anti-Fas (CD95) antibodies, which are integral for studies on T cell activation and apoptosis pathways.

Key co-used antibodies and proteins:

• Anti-CD3 antibodies: Frequently paired with MFL3 to stimulate T cell activation and analyze responses in immunological studies.
• Anti-Fas (CD95) antibodies: Used to investigate Fas/FasL interactions in apoptotic signaling in immune cells.
• Fluorescently labeled antibodies: In flow cytometry, MFL3 is commonly used alongside antibodies for cell surface markers to enable multiparametric analysis of immune cell subsets.
• Markers for T cell subsets: Antibodies against CD4, CD8, and other lineage markers are often included for immune cell phenotyping in studies involving MFL3.
• Additional apoptosis and immune regulation proteins: While anti-CD3 and anti-Fas are the most cited, antibodies targeting other molecules in cell death pathways or immune regulation can also be part of multi-antibody panels, depending on the experimental aim.

These combinations allow for detailed dissection of the Fas/FasL pathway in immune regulation, apoptosis, and T cell biology, and are considered standard in flow cytometric and functional in vivo studies.

Key findings from citations of clone MFL3 in scientific literature highlight its role as a monoclonal antibody specific for mouse Fas Ligand (FasL, CD178), with applications in both detection (e.g., flow cytometry) and functional blockade of FasL-mediated signaling in immune research.

Essential context and supporting details:

• Specificity: Clone MFL3 selectively binds to mouse FasL, a type II transmembrane glycoprotein that is part of the TNF superfamily and is primarily expressed on activated T cells, NK cells, and certain immune-privileged tissues (e.g., eye, testis). This binding is specific for FasL and is commonly used for identification or quantification of FasL-expressing cells.
• Functional blockade: MFL3 is widely used to block FasL function in vivo and in vitro, allowing researchers to investigate the role of Fas–FasL signaling pathways, particularly in immune regulation and apoptosis. This neutralization approach has been instrumental in dissecting the contribution of FasL-mediated cytotoxicity in various disease models, including autoimmune disease and chronic inflammation.
• Mechanistic insights: Studies using MFL3 have demonstrated that antibody-mediated blockade of FasL can reverse functionally relevant immune effects. For example, blocking with clone MFL3 was shown to completely reverse anti-CD3 antibody-induced Th1 cell apoptosis, highlighting FasL's key role in T cell deletion mechanisms.
• Technical applications: MFL3 is validated for use in multiple platforms, most notably flow cytometry, where it enables quantitative and qualitative analysis of FasL expression on cell populations.

Additional relevant information:

• Comparison with other clones: MFL3 is often cited alongside similar clones (such as MFL4), with both being effective at blocking or detecting FasL, but MFL3 enjoys particularly broad citation for functional blocking studies.
• Role in apoptosis research: By enabling manipulation of FasL-mediated signaling, MFL3 has contributed extensively to characterizing Fas-dependent apoptotic pathways and their relevance to T cell homeostasis, autoimmune regulation, and immune privilege.
• Detection sensitivity: The antibody has been optimized for high sensitivity and specificity in both standard and high-parameter flow cytometric panels.

In summary, clone MFL3 is a benchmark reagent for investigating FasL biology in mice, crucial for both phenotypic analysis and mechanistic dissection of FasL's immune functions.

Dosing regimens for clone MFL3 (anti-mouse Fas Ligand, FasL) vary across different mouse models, with no universal standard, and are often tailored to the experimental design, disease model, and objective of FasL blockade or detection. Published protocols demonstrate significant differences in dose, frequency, and administration route, reflecting variability in both purpose and biological context.

Key variations in dosing regimens:

• Dosage Amounts: Reported doses of MFL3 in vivo commonly range from 100 µg to 250 µg per mouse per injection, though some protocols use as little as 50 µg or as much as 500 µg, depending on the model and desired degree of Fas pathway inhibition.
• Frequency and Duration: In tumor immunology or autoimmune disease studies, MFL3 is typically administered every 2–4 days over periods ranging from 1–2 weeks. For acute depletion studies, single high-dose injections may be used.
• Route of Administration: The most common route is intraperitoneal injection (i.p.), but intravenous (i.v.) administration is occasionally employed for rapid systemic effects.
• Model-Dependent Adjustments:
  • In syngeneic tumor models, protocols often use 200 µg i.p., administered every 3 days.
  • In autoimmunity or graft-versus-host studies, some protocols employ 150–250 µg i.p. twice weekly for 2–3 weeks.
  • For acute in vivo depletion, single doses (e.g., 250 µg i.p.) may be sufficient, while chronic models require repeated administrations.
• Analytical and Detection Use: For flow cytometry or tissue staining, much lower concentrations are used (typically ≤0.5 µg per million cells/test).

No single regimen is universally accepted:
Researchers are advised to empirically optimize dosage for each strain, model, and target tissue, and to consult the literature specific to the mouse model or disease context being studied. MFL3 demonstrates consistent reactivity across a broad range of mouse strains.

Summary Table: MFL3 Dosing Variables

Specific dosing protocols should be checked in the primary literature or validated manufacturer datasheets for the relevant disease model or experimental system.